Evaluating minimally invasive surgery for early-stage ovarian cancer
Retrospective Evaluation of Minimally-Invasive Surgical Strategies in Ovarian Neoplasms (REMISSION Study)
This study is trying to see if minimally invasive surgery for early-stage ovarian cancer is safer and more effective than traditional open surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Sex | Female |
| Sponsor | Università degli Studi dell'Insubria Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Varese, Varese) |
| Trial ID | NCT06879730 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the outcomes of patients with early-stage epithelial ovarian cancer who have undergone minimally invasive surgery, such as laparoscopic or robotic techniques. It aims to assess post-surgery complications, including rates of readmission and re-operation, as well as cancer outcomes like survival rates and the incidence of cancer upstaging. The study compares outcomes between patients treated with minimally invasive surgery and those who underwent traditional open surgery. By analyzing these two groups, the study seeks to provide insights into the effectiveness and safety of minimally invasive approaches for this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with early-stage epithelial ovarian cancer who have undergone surgical treatment between January 2014 and December 2023.
Not a fit: Patients who have not completed surgical staging or those who have undergone neoadjuvant chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide evidence supporting the use of minimally invasive surgery as a safer and more effective treatment option for early-stage ovarian cancer.
How similar studies have performed: Other studies have shown promising results with minimally invasive surgical techniques in various cancers, suggesting potential success for this approach in ovarian cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation 2. Patients who underwent surgery between January 2014 and December 2023 3. Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure 4. Patients with final pathology report of Epithelial Ovarian Cancer Exclusion Criteria: 1. Patients who have not performed a complete surgical staging 2. Patients who underwent neoadjuvant chemotherapy 3. Patients with invasive synchronous tumor 4. Patients with no informed consent 5. Patients with ASA class score of 4 or 5
Where this trial is running
Varese, Varese
- Ospedale Filippo del Ponte — Varese, Varese, Italy (Recruiting)
Study contacts
- Study coordinator: Jvan Casarin, Medical Doctor
- Email: j.casarin@uninsubria.it
- Phone: +39 3335384990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.